Replies to post #6751 on Biotech Values

[DewDiligence]

winchem:

>> 40mg end of treatment 207 results appear to be comparable to Mexico trials. There clearly appears to be a dropoff in VA one month after treatment that was not seen during the Phase I/II after both 1 and 3 months in Mexico. The 10 mg results are poorer at all stages. These preliminary results point to the possible need for weekly doses at 40 mg levels to maintain effective treatment [emphasis added].<<

I think that’s a reasonable summary of the “207” data released to date. Your description is far more illuminating than Dr. Levitt’s half-truth that the “207” results are consistent with the Mexican trial. Regards, Dew

[winchem21]

AMD Data update minus high/low readings.

Throwing out the high and low results for each of the AMD trials, here are the averages from the four remaining patients for the data that have been reported on GENR's site.

Date  Mex  40mgst 40mg2nd 10mg 
 Wk3	6.5	6.9	4.3	0.8 
 EOT	8.8	7.8	7.1	2.7 
 2Mon	6.9	2.8	2.9   -1.9  
 4Mon  5.7   -1.5   3.9   -2.0

For the 4 median patients taking 40 mg doses and combining both eyes, there was an average dropoff of about 1 letter per month between 2 and 4 months. This is approximately the same rate of vision loss as shown for untreated patients in an earlier slide.

The 20 mg data and the 10mg 2nd eye data have not been reported to date. Perhaps these missing data are even less compelling.....given GENR's need to finance phase III trials.

wc21